Bristol Myers Squibb Company (NYSE:BMY) Shares Acquired by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 7.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,178 shares of the biopharmaceutical company’s stock after purchasing an additional 1,482 shares during the period. Roman Butler Fullerton & Co.’s holdings in Bristol Myers Squibb were worth $1,231,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Pinney & Scofield Inc. purchased a new stake in Bristol Myers Squibb during the fourth quarter worth about $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $26,000. Fairway Wealth LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $28,000. Transce3nd LLC purchased a new position in Bristol Myers Squibb in the 4th quarter valued at approximately $28,000. Finally, Global Wealth Strategies & Associates raised its holdings in Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 275 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 2.9%

Shares of BMY opened at $47.25 on Wednesday. The stock’s fifty day simple moving average is $48.49 and its 200 day simple moving average is $54.58. Bristol Myers Squibb Company has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The firm has a market capitalization of $96.15 billion, a P/E ratio of 17.70, a price-to-earnings-growth ratio of 1.42 and a beta of 0.38.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company’s revenue was down 5.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($4.40) EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.25%. Bristol Myers Squibb’s payout ratio is currently 92.88%.

Insider Activity

In related news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction dated Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.07% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Argus raised Bristol Myers Squibb to a “hold” rating in a report on Friday, April 25th. Jefferies Financial Group decreased their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research note on Wednesday, April 23rd. Cantor Fitzgerald reissued a “neutral” rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Finally, Piper Sandler started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $58.00.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.